Fibrinogen Replacement during Postpartum Hemorrhage: Comparing Plasma, Cryoprecipitate, and Fibrinogen Concentrate
- 01.12.2025
- Blood Management (KA Tanaka, Section Editor)
Erschienen in:
- Verfasst von
- John J. Kowalczyk
- Michaela K. Farber
- Amir L. Butt
- Erschienen in
- Current Anesthesiology Reports | Ausgabe 1/2025
Abstract
Purpose of Review
This review aims to discuss fibrinogen-rich products—cryoprecipitate and fibrinogen concentrate—for fibrinogen replacement during PPH, as well as the benefits, key studies of use during PPH, and the role of viscoelastic testing.
Recent Findings
In vitro studies demonstrate the superiority of fibrinogen concentrate to correct acquired hypofibrinogenemia. Retrospective and prospective studies evaluating targeted fibrinogen replacement using viscoelastic testing have consistently demonstrated a reduction in total transfused units, fewer plasma units administered, and lower rates of transfusion-associated lung injury and transfusion-associated circulatory overload. Universal prophylactic fibrinogen administration to patients at the onset of PPH does not yield improved clinical outcomes. In studies demonstrating this finding, the median serum fibrinogen concentration at the time of fibrinogen concentrate administration was > 400 mg/dL.
Summary
Fibrinogen replacement shows promise as a treatment for obstetric coagulopathy. However, prophylactic fibrinogen replacement does not decrease blood loss or improve clinical outcomes.
Anzeige
- Titel
- Fibrinogen Replacement during Postpartum Hemorrhage: Comparing Plasma, Cryoprecipitate, and Fibrinogen Concentrate
- Verfasst von
-
John J. Kowalczyk
Michaela K. Farber
Amir L. Butt
- Publikationsdatum
- 01.12.2025
- Verlag
- Springer US
- Erschienen in
-
Current Anesthesiology Reports / Ausgabe 1/2025
Elektronische ISSN: 2167-6275 - DOI
- https://doi.org/10.1007/s40140-024-00663-8
Dieser Inhalt ist nur sichtbar, wenn du eingeloggt bist und die entsprechende Berechtigung hast.
